natgillin/translations-raw huggingface dataset:
Rivastigmine should be administered twice a day, with morning and evening meals. 
Rivastigmin je treba dajati dvakrat na dan, ob zajtrku in večerji.
In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. 
Če preveliko odmerjanje spremljata huda navzea in bruhanje, je treba pretehtati možnost uporabe antiemetikov.
The effective dose is 3 to 6 mg twice a day; to achieve maximum therapeutic benefit patients should be maintained on their highest well tolerated dose. 
Učinkoviti odmerek je 3 do 6 mg dvakrat na dan; za doseganje največjega terapevtskega učinka je treba uporabiti največji odmerek, ki ga bolniki dobro prenašajo.
Administration of rivastigmine with food delays absorption (tmax) by 90 min and lowers Cmax and increases AUC by approximately 30 %. 
Uporaba rivastigmina skupaj s hrano upočasni absorpcijo (tmax) za 90 min in zmanjša vrednost Cmax ter poveča vrednost AUC za približno 30 %.
Rivastigmine is rapidly and extensively metabolised (half-life in plasma approximately 1 hour), primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite. 
Rivastigmin se presnavlja hitro in v veliki meri (razpolovni čas v plazmi je približno 1 ur), predvsem s holinesterazno hidrolizo v dekarbamiliran presnovek.
Symptomatic treatment for other adverse reactions should be given as necessary. 
Po potrebi je treba uporabiti simptomatsko zdravljenje za druge neželene reakcije.
If you forget to take Rivastigmine Teva 
Če ste pozabili vzeti zdravilo Rivastigmine Teva
Total plasma clearance of rivastigmine was approximately 130 l/h after a 0.2 mg intravenous dose and decreased to 70 l/h after a 2.7 mg intravenous dose. 
Po 0,2-miligramskem intravenskem odmerku je bil skupni plazemski očistek rivastigmina približno 130 l/h mg, po 2,7-miligramskem intravenskem odmerku pa se je zmanjšal na 70 l/h.
An initial dose of 0.03 mg/kg intravenous atropine sulphate is recommended, with subsequent doses based on clinical response. 
Priporočen je intravenski odmerek 0,03 mg/kg atropinijevega sulfata, naknadni odmerki pa naj temeljijo na kliničnem odzivu.
In addition, Rivastigmine Teva 3 mg, 4.5 mg and 6 mg hard capsules contain red iron oxide (E172) and yellow iron oxide (E 172). 
Zdravila Rivastigmine Teva 3 mg, 4,5 mg in 6 mg trde kapsule vsebujejo tudi rdeči železov oksid (E172) in rumeni železov oksid (E 172).
THE MARKETING AUTHORISATION HOLDER Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, Section 4.2 ). 
Izdaja zdravila je le na recept (glejte Dodatek I: povzetek glavnih značilnosti zdravila, poglavje 4.2).
Extrapyramidal symptoms (including worsening of Parkinson's disease) 
Ekstrapiramidni simptomi (vključno s poslabšanjem Parkinsonove bolezni)
• Liver disorders (yellow skin, yellowing of the whites of eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite) 
• jetrne motnje (porumenelost kože, porumenelost očesnih beločnic, nenormalno temen urin ali nepojasnjena slabost v želodcu, bruhanje, utrujenost in izguba apetita)
Cardiac arrhythmia (e.g. bradycardia, atrio-ventricular block, atrial fibrillation and tachycardia) 
Srčna aritmija (npr. bradikardija, atrioventrikularni blok, atrijska fibrilacija in tahikardija)
As a consequence, rivastigmine has minor or moderate influence on the ability to drive and use machines. 
Posledično ima rivastigmin blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Pharmacotherapeutic group: anticholinesterases, ATC code: N06DA03 
Farmakoterapevtska skupina: antiholinesteraze, oznaka ATC: N06DA03.
Caution is recommended in treating patients predisposed to such diseases. 
Pri zdravljenju bolnikov, ki so nagnjeni k tem boleznim, je priporočena previdnost.
Similarly a larger treatment effect was observed in those patients with visual hallucinations (see Table 6). 
Podobno so boljši učinek zdravljenja opazili pri bolnikih z vizualnimi halucinacijami (glejte tabelo 6).
Elevated liver function tests 
Zvišane vrednosti jetrnih laboratorijskih preiskav
If any of these side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 
Če katerikoli neželeni učinek postane resen ali če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Unchanged rivastigmine is not found in the urine; renal excretion of the metabolites is the major route of elimination. 
V urinu niso odkrili nespremenjenega rivastigmina; glavna pot izločanja je izločanje presnovkov skozi ledvice.
Do not open or crush the capsules. 
• Kapsul ne odpirajte in ne drobite.
These include the ADAS-Cog (a performance based measure of cognition), the CIBIC-Plus (a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.). 
Ta orodja so ADAS-Cog (meritev kognicije na podlagi učinkovitosti), CIBIC-Plus (obsežna globalna ocena bolnika, pri kateri zdravnik upošteva informacije skrbnika), in PDS (skrbnikova ocena dejavnosti v vsakdanjem življenju, vključno z osebno higieno, prehranjevanjem, oblačenjem, gospodinjskimi opravili, kot so nakupovanje, ohranjanje zmožnosti orientacije v okolju in sodelovanje pri dejavnostih, povezanih s financami, itd.).
Based on evidence from in vitro and animal studies the major cytochrome P450 isoenzymes are minimally involved in rivastigmine metabolism. 
Na podlagi študij in vitro in pri živalih so ugotovili, da pomembnejši izoencimi citokroma P450 minimalno sodelujejo v presnovi rivastigmina.
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with rivastigmine in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms. 
V tabeli 3 so navedena števila in odstotki bolnikov iz specifične 24-tedenske klinične študije z rivastigminom pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, z vnaprej opredeljenimi neželenimi dogodki, ki lahko odražajo poslabšanje simptomov Parkinsonove bolezni.
Special Populations 
Posebne skupine
Although a treatment effect was demonstrated in the overall study population, the data suggested that a larger treatment effect relative to placebo was seen in the subgroup of patients with moderate dementia associated with Parkinson's disease. 
Čeprav so učinek zdravljenja pokazali pri celotni populaciji bolnikov, ki so sodelovali v študiji, podatki kažejo, da so relativno boljši učinek glede na placebo opazili v podskupini bolnikov z zmerno demenco, povezano s Parkinsonovo boleznijo.
Rivastigmine Teva hard capsules are available in blister packs of 28, 56 and 112 capsules, perforated blisters containing 50 x 1 capsules, and bottles containing 250 capsules. 
Zdravilo Rivastigmine Teva trde kapsule je na voljo v pretisnih omotih po 28, 56 in 112 kapsul, perforiranem pretisnem omotu s 50 x 1 kapsulo ter v steklenicah po 250 kapsul.
Very common • Trembling 
Zelo pogosti • tresenje
Some people who have accidentally taken too much Rivastigmine Teva have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. 
Pri nekaterih ljudeh, ki so nehote vzeli preveč zdravila Rivastigmine Teva, je prišlo do navzee (slabosti s siljenjem na bruhanje), bruhanja, driske, visokega krvnega tlaka in halucinacij.
Or: 
Ali:
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative StudyClinician's Global Impression of Change). 
Učinkovitost so prikazali z dvema neodvisnima lestvicama, s katerima so stanje bolnikov ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot je prikazano v tabeli 5 spodaj: ADAS-Cog, meritev kognicije in globalna meritev ADCS-CGIC (Kooperativna študija Alzheimerjeve bolezni - zdravnikov globalni vtis o spremembi - Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change).
Rivastigmine interacts with its target enzymes by forming a covalently bound complex that temporarily inactivates the enzymes. 
Rivastigmin učinkuje na svoje ciljne encime tako, da tvori kovalentni kompleks, ki jih začasno inaktivira.
It is also used for the treatment of dementia in patients with Parkinson's disease. 
Uporablja se tudi za zdravljenje demence pri bolnikih s Parkinsonovo boleznijo.
Therefore, women on rivastigmine should not breast-feed 
Zato ženske, ki jemljejo rivastigmin, ne smejo dojiti.
A. MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE
Worsening of Parkinson's disease 
Poslabšanje Parkinsonove bolezni
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose 104 times the maximum clinical exposure. 
Pri standardnem nizu preskusov in vitro in in vivo rivastigmin ni bil mutagen, razen v preskusu kromosomskih aberacij na perifenih limfocitih človeka, pri odmerku, ki je bil 104-krat večji od največje klinične izpostavljenosti.
Like all medicines, Rivastigmine Teva can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Rivastigmine Teva neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
For rivastigmine no clinical data on exposed pregnancies are available. 
Kliničnih podatkov o uporabi rivastigmina med nosečnostjo ni.
The use of rivastigmine in patients with severe dementia of Alzheimer's disease or associated with Parkinson's disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore the use in these patient populations is not recommended. 
Uporabe rivastigmina pri bolnikih s hudo Alzheimerjevo demenco ali demenco, povezano s Parkinsonovo boleznijo, drugimi vrstami demence ali drugimi vrstami okvar spomina (npr. z zmanjšanjem kognitivnih funkcij, povezanim s starostjo) niso raziskovali, zato uporaba pri teh populacijah bolnikov ni priporočena.
28 hard capsules 50 x 1 hard capsules 56 hard capsules 112 hard capsules 
Pretisni omoti 28 trdih kapsul 50 x 1 trda kapsula 56 trdih kapsul 112 trdih kapsul
No effects on fertility or embryofoetal development were observed in rats and rabbits, except at doses related to maternal toxicity. 
Pri podganah in kuncih niso opazili nikakršnih učinkov na plodnost ali razvoj zarodka/plodu, razen pri odmerkih, ki so bili toksični za mater.
It is preferable to avoid the use of Rivastigmine Teva during pregnancy, unless clearly necessary. 
V nosečnosti se je priporočljivo izogibati uporabi zdravila Rivastigmine Teva, razen če je nujno potrebno.
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10 % improvement on the PDS. 
v teh študijah je bilo klinično pomembno izboljšanje vnaprej opredeljeno kot izboljšanje rezultata ADAS-Cog za vsaj 4 točke, izboljšanje rezultata CIBIC-Plus, ali vsaj 10-odstotno izboljšanje rezultata PDS.
Capsule shell - titanium dioxide (E171), gelatin and ink used for imprinting Black S-1-17822/S-117823 (shellac glaze-45% in ethanol containing iron oxide black, N-butyl alcohol, isopropyl alcohol, propylene alcohol and ammonium hydroxide). 
Ovoj kapsule - titanov dioksid (E171), želatina in črnilo za tisk Black S-1-17822/S-1-17823 (glazura iz šelaka - 45 % v etanolu, ki vsebuje črni železov oksid, N-butilni alkohol, izopropilni alkohol, propilenglikol in amonijev hidroksid).
In view of its pharmacodynamic effects, rivastigmine should not be given concomitantly with other cholinomimetic substances and might interfere with the activity of anticholinergic medicinal products. 
Zaradi farmakodinamskih učinkov se rivastigmin ne sme dajati sočasno z drugimi holinomimetiki, lahko pa tudi vpliva na delovanje antiholinergičnih zdravil.
If treatment is interrupted for more than several days, it should be re-initiated at 1.5 mg twice daily to reduce the possibility of adverse reactions (e.g. vomiting). 
Če se zdravljenje prekine za več kot nekaj dni, ga je treba začeti znova pri odmerku 1,5 mg dvakrat na dan, da se zmanjša možnost neželenih učinkov (npr. bruhanja).
These events led to the discontinuation of rivastigmine in some cases (e.g. discontinuations due to tremor 1.7 % on rivastigmine vs 0 % on placebo). 
V nekaterih primerih so zaradi teh dogodkov zdravljenje z rivastigminom prekinili (npr. pri zdravljenju z rivastigminom so zaradi tremorja prekinili 1,7 % zdravljenj, pri placebu pa 0 %).
In other cases, rivastigmine has been discontinued (see section 4.8). 
V drugih primerih so zdravljenje z rivastigminom prekinili (glejte poglavje 4.8).
When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals. 
Če so izpostavljenost rivastigminu in njegovim presnovkom normalizirali glede na telesno površino, je bila izpostavljenost približno enakovredna največjem priporočenem odmerku pri človeku, 12 mg/dan; vendar so v primerjavi z največjim odmerkom pri človeku, pri živalih dosegli 6-krat večji odmerek.
In animals, rivastigmine crosses the placenta and is excreted into milk. 
Pri živalih rivastigmin prehaja skozi placento in se izloča v mleko.
The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS. 
Za sekundarno opredelitev odziva je bilo potrebno izboljšanje rezultata ADAS-Cog za 4 točke ali več, odsotnost poslabšanja rezultata CIBIC-Plus, in odsotnost poslabšanja rezultata PDS.
However, due to increased exposure in these populations dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal or hepatic impairment might experience more adverse reactions (see sections 4.4 and 5.2). 
Vendar se je treba zaradi povečane izpostavljenosti pri bolnikih pri teh populacijah natančno ravnati po priporočilih, naj se odmerjanje titrira glede na posameznikovo prenašanje, saj je pri bolnikih s klinično pomembno okvaro ledvic ali jeter lahko število neželenih učinkov večje (glejte poglavji 4.4 in 5.2).
This medicinal product does not require any special storage instructions. 
Za shranjevanje zdravila niso potrebna posebna navodila.
Activity of the enzyme returns to baseline levels about 9 hours after the maximum inhibitory effect has been achieved. 
Aktivnost encima se vrne na izhodiščno raven približno po 9 urah po doseženem največjem zaviralnem učinku.
However a greater treatment effect was seen in Parkinson's disease patients with moderate dementia. 
Vendar so večji učinek zdravljenja opazili pri bolnikih s Parkinsonovo boleznijo z zmerno demenco.
Oral studies in pregnant rats and rabbits gave no indication of teratogenic potential on the part of rivastigmine. 
Peroralne študije pri brejih podganah niso pokazale nikakršnega teratogenega potenciala rivastigmina.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10 - 24. 
Bolniki, ki so sodelovali v študiji so imeli rezultat MMSE (kratek preizkus spoznavnih sposobnosti - MiniMental State Examination) 10 - 24.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. 
Simptomatsko zdravljenje blage do zmerne Alzheimerjeve demence.
Similarly a larger effect was observed in Parkinson's disease patients with visual hallucinations (see section 5.1). 
Podobno so večji učinek opazili pri bolnikih s Parkinsonovo boleznijo z vidnimi halucinacijami (glejte poglavje 5.1).
• Aggression , feeling restless 
• agresivnost, občutek nemira
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia or dementia associated with Parkinson's disease. 
4.2 Odmerjanje in način uporabe Zdravljenje mora začeti in nadzirati zdravnik z izkušnjami v diagnosticiranju in zdravljenju Alzheimerjeve demence ali demence, povezane s Parkinsonovo boleznijo.
Rivastigmine is an acetyl- and butyrylcholinesterase inhibitor of the carbamate type, thought to facilitate cholinergic neurotransmission by slowing the degradation of acetylcholine released by functionally intact cholinergic neurones. 
Rivastigmin je zaviralec acetil- in butirilholinesteraze karbamatnega tipa, za katerega menijo, da pomaga pri holinergični nevrotransmisiji tako, da upočasni razgradnjo acetilholina, ki ga sproščajo funkcionalno intaktni holinergični nevroni.
Patients with mild dementia (MMSE 18-24) 
Bolniki z blago demenco (MMSE
Children Rivastigmine is not recommended for use in children. 
Uporaba rivastigmina pri otrocih ni priporočljiva.
Care must be taken when using rivastigmine in patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8). 
Pri uporabi rivastigmina pri bolnikih s sindromom bolnega sinusnega vozla ali motnjami prevodnosti (sinuatrialni blok, atrioventrikularni blok) je potrebna previdnost (glejte poglavje 4.8).
Treatment effect has not been studied in placebo-controlled trials beyond 6 months. 
V preskušanjih, nadzorovanih s placebom učinka zdravljenja niso raziskovali dlje kot 6 mesecev.
Other side effects seen with Rivastigmine transdermal patches and which may occur with hard capsules: 
Drugi neželeni učinki, ki so jih opažali pri uporabi transdermalnih obližev in bi se lahko pojavili tudi pri uporabi trdih kapsul: Pogosti
No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and rivastigmine. 
Neugodnih učinkov na srčno prevodnost po sočasni uporabi digoksina in rivastigmina niso opazili.
If treatment is interrupted for more than several days, it should be re-initiated at 1.5 mg twice daily. 
Če se zdravljenje prekine za več kot nekaj dni, ga je treba začeti znova pri odmerku 1,5 mg dvakrat na dan.
4.9 Overdose Symptoms 
4.9 Preveliko odmerjanje Simptomi
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON 
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM • POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU
During therapy patient's weight should be monitored. 
Med zdravljenjem je treba spremljati telesno maso bolnikov.
In this leaflet: What Rivastigmine Teva is and what it is used for 
KAJ JE ZDRAVILO RIVASTIGMINE TEVA IN ZA KAJ GA UPORABLJAMO
The recommended maximum daily dose is 6 mg twice a day. 
Priporočen največji dnevni odmerek je 6 mg dvakrat na dan.
What Rivastigmine Teva looks like and contents of the pack 
Izgled zdravila Rivastigmine Teva in vsebina pakiranja
INFORMATION IN BRAILLE Rivastigmine Teva 1.5 mg 
PODATKI V BRAILLOVI PISAVI Rivastigmine Teva 1,5 mg
Patients with severe hepatic impairment have not been studied (see section 4.4). 
Bolnikov s hudo jetrno okvaro niso raziskovali (glejte poglavje 4.4).
Take special care with Rivastigmine Teva 
Bodite posebno pozorni pri jemanju zdravila Rivastigmine Teva
The increase in prothrombin time induced by warfarin is not affected by administration of rivastigmine. 
Uporaba rivastigmina ne vpliva na povečanje protrombinskega časa, ki ga povzroči varfarin.
You should not breast-feed during treatment with Rivastigmine Teva. 
Med zdravljenjem z zdravilom Rivastigmine Teva ne smete dojiti.
According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances. 
Na podlagi presnove je videti, da presnovne interakcije z drugimi zdravili niso verjetne, vendar lahko rivastigmin zavira presnovo drugih snovi, ki jo uravnava butirilholinesteraza.
If you take more Rivastigmine Teva than you should If you accidentally take more Rivastigmine Teva than you should, inform your doctor. 
Če nehote vzamete več zdravila Rivastigmine Teva, kot bi smeli, obvestite svojega zdravnika.
Clinical studies in dementia associated with Parkinson's disease The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase. 
Klinične študije pri demenci, povezani s Parkinsonovo boleznijo Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom nadzorovani osrednji študiji in naknadni 24-tedenski odprti fazi.
Caution is recomemended when selecting anaesthetic agents. 
Pri izbiri anestetika je priporočena previdnost.
Thus, rivastigmine may have an ameliorative effect on cholinergic-mediated cognitive deficits in dementia associated with Alzheimer's disease and Parkinson's disease. 
Zato rivastigmin zmanjša holinergični primanjkljaj pri demenci, povezani z Alzheimerjevo in Parkinsonovo boleznijo.
Do not use Rivastigmine Teva after the expiry date that is stated on the carton. 
Zdravila Rivastigmine Teva ne smete uporabljati po izteku roka uporabnosti, ki je naveden na zunanji ovojnini.
No evidence of carcinogenicity was found in studies in mice and rats at the maximum tolerated dose, although the exposure to rivastigmine and its metabolites was lower than the human exposure. 
V študijah pri miših in podganah z največjim odmerkom, ki so ga živali prenašale, niso ugotovili nikakršnih dokazov za kancerogenost, vendar je bila izpostavljenost rivastigminu in njegovim presnovkom manjša kot pri človeku.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. 
Simptomatsko zdravljenje blage do zmerne demence pri bolnikih z idiopatsko Parkinsonovo boleznijo.
Yellow iron oxide (E 172) 
rdeči železov oksid (E 172)
Very rare Not known 
Zelo redki Neznana
• High blood pressure 
Zelo redki • visok krvni tlak
If adverse reactions persist, the daily dose should be temporarily reduced to the previous well-tolerated dose or the treatment may be discontinued. 
Če se neželeni učinki ne prenehajo, je treba dnevni odmerek začasno zmanjšati na prejšnjega, ki ga je bolnik še dobro prenašal, ali prekiniti zdravljenje.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Teva Pharma B.V. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Teva Pharma B.V.
In healthy young men, an oral 3 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40 % within the first 1.5 hours after administration. 
Pri zdravih mladih moških peroralni 3-miligramski odmerek zmanjša aktivnost acetilholinesteraze (AChE) v cerebrospinalni tekočini za približno 40 % v prvi 1,5 uri po uporabi.
Re-initiation of therapy: 
Ponoven začetek zdravljenja:
Total patients studied Total patients with pre-defined AE(s) Tremor 
Skupno število bolnikov v študiji Skupno število bolnikov z vnaprej opredeljenimi neželenimi dogodki
Slow heart beat and fainting may also occur. 
Lahko pride tudi do počasnega utripa srca in omedlevice.
Female patients in clinical studies were found to be more susceptible than male patients to gastrointestinal adverse reactions and weight loss. 
V kliničnih študijah so ugotovili, da so bolnice bolj dovzetne za gastrointestinalne neželene učinke in izgubo telesne mase kot moški bolniki.
Like other cholinomimetics, rivastigmine may exacerbate or induce extrapyramidal symptoms. 
Kot drugi holinomimetiki, lahko tudi rivastigmin poslabša ali sproži ekstrapiramidalne simptome.